Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
TargED Biopharmaceuticals, a Netherlands-based thermobolytic clot treatment spinout of UMC Utrecht, picked up €39m ($44.2m) in a series A round today backed by the UMC-backed Utrecht Health Seed Fund. The round was co-led by Andrea Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures. It also included BioGeneration Ventures-managed First Fund and Curie Capital. TargED had secured $1.7m in seed funding in 2020 from investors also including Utrecht Health Seed Fund.
Porotech, a UK-based microdisplay technology…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
